CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit.

Autor: Yi F; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Cohen T; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.; Department of Pediatric Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA., Zimmerman N; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Dündar F; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.; Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA., Zumbo P; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA.; Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA., Eltilib R; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Brophy EJ; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Arkin H; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Feucht J; Center for Cell Engineering, MSKCC, New York, NY, USA.; Cluster of Excellence iFIT, University Children's Hospital Tübingen, Tübingen, Germany., Gormally MV; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.; Cell Therapy Service, Department of Medicine, MSKCC, New York, NY, USA., Hackett CS; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Kropp KN; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Etxeberria I; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Chandran SS; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA., Park JH; Center for Cell Engineering, MSKCC, New York, NY, USA.; Cell Therapy Service, Department of Medicine, MSKCC, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Hsu KC; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.; Center for Cell Engineering, MSKCC, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Sadelain M; Center for Cell Engineering, MSKCC, New York, NY, USA.; Department of Immunology, Sloan Kettering Institute, MSKCC, New York, NY, USA., Betel D; Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA., Klebanoff CA; Human Oncology and Pathogenesis Program (HOPP), Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.; Center for Cell Engineering, MSKCC, New York, NY, USA.; Cell Therapy Service, Department of Medicine, MSKCC, New York, NY, USA.; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.; Parker Institute for Cancer Immunotherapy, New York, NY, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Mar 01. Date of Electronic Publication: 2024 Mar 01.